GlassScriptPhysician profile
Brandy Kelley Junkin
NPI 1902259443
$8,500.38
in general payments reported to CMS, 2019-2025
50 companies · $1,542 in 2025
The $1,542 reported for 2025 was more than what 92% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,761 · 2022: $1,875 · 2023: $1,682 · 2024: $1,640 · 2025: $1,542.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,821 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,820.92 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,484.11 | 2021-2025 | |
| Amgen INC. | $580.43 | 2021-2024 | Repatha, Otezla, Evenity |
| Otsuka America Pharmaceutical, INC. | $566.20 | 2021-2025 | Rexulti, Abilify Asimtufii |
| Bayer Healthcare Pharmaceuticals INC. | $514.98 | 2022-2025 | |
| Novo Nordisk INC | $496.72 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
| Daiichi Sankyo INC. | $355.37 | 2021-2023 | Injectafer |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $330.71 | 2022-2025 | Caplyta |
| Lilly USA, LLC | $291.97 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $251.71 | 2022-2024 | |
| Neurocrine Biosciences, INC. | $219.09 | 2022-2025 | Ingrezza |
| Astellas Pharma US INC | $189.59 | 2021-2024 | Veozah |
| Teva Pharmaceuticals USA, INC. | $185.73 | 2021-2025 | Austedo Xr, Austedo Xr |
| Astrazeneca Pharmaceuticals LP | $161.52 | 2021-2025 | Enhertu, Airsupra, Breztri |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $160.56 | 2021-2022 | |
| Indivior INC. | $155.65 | 2021-2025 | Sublocade |
Show all 50 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brandy Junkin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.